Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$17 Mln
P/E Ratio
--
P/B Ratio
1.83
Industry P/E
--
Debt to Equity
0.19
ROE
-0.98 %
ROCE
-88.48 %
Div. Yield
0 %
Book Value
0.94
EPS
-1.72
CFO
$-106.39 Mln
EBITDA
$-300.88 Mln
Net Profit
$-303.62 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Cocrystal Pharma (COCP)
| -15.40 | 8.16 | -19.05 | 9.84 | -34.74 | -31.02 | -42.40 |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Cocrystal Pharma (COCP)
| 17.29 | -11.79 | -75.00 | -52.21 | 174.47 | -86.24 | -39.83 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.31 | 6,904.81 | -- | 38.11 | |
| 71.71 | 7,574.08 | 58.3 | 23.56 | |
| 59.16 | 11,448.88 | 394.4 | 0.76 | |
| 8.13 | 9,704.70 | -- | -3.24 |
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to... treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington. Read more
Co-Founder, Chairman of the Board, Chief Scientist & Chairman of Scientific Advisory Board
Dr. Roger D. Kornberg Ph.D.
Co-Founder, Chairman of the Board, Chief Scientist & Chairman of Scientific Advisory Board
Dr. Roger D. Kornberg Ph.D.
Headquarters
Bothell, WA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Cocrystal Pharma Inc (COCP) stood at $ 13 Mln as on 31-Dec-24
The share price of Cocrystal Pharma Inc (COCP) is $1.71 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Cocrystal Pharma Inc (COCP) has given a return of -34.74% in the last 3 years.
Cocrystal Pharma Inc (COCP) has a market capitalisation of $ 17 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Cocrystal Pharma Inc (COCP) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Cocrystal Pharma Inc (COCP) and enter the required number of quantities and click on buy to purchase the shares of Cocrystal Pharma Inc (COCP).
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.
The CEO & director of Dr. Roger D. Kornberg Ph.D.. is Cocrystal Pharma Inc (COCP), and CFO & Sr. VP is Dr. Roger D. Kornberg Ph.D..
There is no promoter pledging in Cocrystal Pharma Inc (COCP).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,122
|
|
|
932
|
|
|
731
|
|
|
670
|
| Cocrystal Pharma Inc. (COCP) | Ratios |
|---|---|
|
Return on equity(%)
|
-97.5
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Cocrystal Pharma Inc (COCP) was $0 Mln.
$0.25
(
